Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
复制标题
DOI：
10.2174/187152808786848360
复制
发表时间：
2008-12-01
期刊：
影响因子：
--
通讯作者：
Buer, Jan
中科院分区：
文献类型：
--
作者：
Hansen, Wiebke;Westendorf, Astrid M.;Buer, Jan
调节性T（Treg）细胞正在成为调节不同免疫应答的关键参与者，从而代表了用于多种免疫性疾病的治疗干预的潜在候选者。虽然功能的减少或丧失在癌症治疗期间是有益的，但Treg细胞功能的诱导和/或扩增可能有助于在自身免疫、过敏和炎症期间干扰移植医学中不需要的免疫应答。然而，更好地理解Treg细胞生物学是在体内免疫应答期间特异性调节其功能的先决条件。在本综述中，我们将讨论目前的概念，不同的细胞类型，组件和一些新的表面受体表达的Treg细胞，即Neuropilin-1，CD 83和G蛋白偶联受体83，这可能是有前途的目标调节Treg细胞的功能在人类疾病。
Regulatory T (Treg) cells are emerging as key players in the regulation of different immune responses, thereby representing potential candidates for therapeutic interventions in a broad variety of immunological disorders. While the reduction or loss in function would be of benefit during the treatment of cancer, induction and/or expansion of Treg cell function might be helpful to interfere with unwanted immune responses in transplantation medicine, during autoimmunity, allergy and inflammation. However, a better understanding of Treg cell biology is a prerequisite to specifically modulate its function during immune responses in vivo. In the present review we will discuss current concepts on different cell types, components and some novel surface receptors expressed by Treg cells, namely Neuropilin-1, CD83 and G protein-coupled receptor 83 which might represent promising targets for the modulation of Treg cell function in human disease.